 |
市场调查报告书
商品编码
1816821
非小细胞肺癌的标靶治疗市场:KOL的洞察KOL Insights - Non-Small Cell Lung Cancer - Targeted Therapies |
||||||
本报告深入分析了来自美国和欧洲的12位关键意见领袖的观点，全面探讨了非小细胞肺癌 (NSCLC) 标靶治疗的前景。本报告深入探讨了目前和未来的治疗途径，重点关注Tagrisso、Lybrevat和Enhertz等成熟和新兴疗法的作用。深入了解新製剂带来的课题和机会、近期药物审批的影响以及不断发展的治疗方案。透过探讨酪胺酸激酶抑制剂、KRAS抑制剂和其他标靶药物的专家观点，本报告为NSCLC治疗的未来发展方向提供了宝贵的见解。
关键问题解答
- 阿斯特捷利康的Tagrisso目前是如何应用的？
- Genmab/强生公司 Rybrevant 的现今与未来用途。
- Livelevant 的皮下製剂将如何影响其临床应用？
- 对新型 EGFR 和 HER 酪胺酸激酶抑制剂的预期。
- Enhertz 在非小细胞肺癌 (NSCLC) 临床实务中是如何应用的？
- 对 Datroway、Emrelis 和 Ensacove 等近期核准药物的看法。
- 专家如何使用 ALK 抑制剂？他们认为哪种抑制剂比较可取？
- 正在研发的 KRAS 抑制剂在 NSCLC 治疗中的潜力。
- 专家如何预测 MET 抑制剂、RET 抑制剂、ROS1 抑制剂和 BRAF 抑制剂将如何改变治疗方案？
- 预计 NSCLC 标靶治疗的格局在近期和中期内将如何变化？
领导品牌
|
|
与会专家名单
- 杜克大学医学院助理教授兼肿瘤内科医师美国
- Jeffrey A. Brown 和 Barbara Horowitz-Brown，美国罗德岛州普罗维登斯市生命跨度癌症研究所副教授、胸腔肿瘤学主任兼转化医学教授
- 美国马里兰州约翰霍普金斯医学院胸腔肿瘤临床研究计画主任兼肿瘤学副教授
- 英国伯明罕伊丽莎白女王医院临床肿瘤顾问医师
- 法国马赛艾克斯-马赛大学马赛公立医院教授兼主任
- 法国维尔瑞夫古斯塔夫‧鲁西医学院胸腔肿瘤学组长
研究方法：
"治疗趋势" 报告是世界顶尖关键意见领袖 (KOL) 就重点疾病领域当前和未来治疗前景开展的合作研究计画。我们的报告透过对关键产业领袖的深入访谈编写而成。关键意见领袖 (KOL) 的甄选是基于严格的标准，包括全球知名度、临床专业知识以及在其治疗领域的影响力。每次访谈都配有精心设计的讨论指南。这些指南由我们与关键意见领袖合作开发，并由行业专家进行同行评审，确保问题全面且与当前市场动态相关。每份报告发布后，我们会持续 12 个月的市场监测，及时提供关键意见领袖对重大新闻事件、市场变化和市场发展的更新。
我们的报告有何独特之处？
FirstWord Reports 是值得信赖的行业领导者，专注于製药领域，为生物製药专业人士和决策者提供详尽且可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助我们的客户掌握新兴趋势并有效应对复杂课题。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访谈和数据，以及持续的市场监测，让您全面了解市场动态。我们的报告涵盖 40 多个活跃疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报，以及行业专家对医疗事务、数位健康、销售和营销、市场准入等领域问题的见解，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。
Explore the comprehensive landscape of targeted therapies in non-small cell lung cancer (NSCLC) with this detailed report, which analyzes insights from 12 key opinion leaders across the US and Europe. This report delves into the current and future treatment pathways, focusing on the role of established and novel therapies such as Tagrisso, Rybrevant, and Enhertu. Gain a deeper understanding of the challenges and opportunities presented by new formulations, the impact of recent drug approvals, and the evolving treatment algorithms. By examining expert perspectives on tyrosine kinase inhibitors, KRAS inhibitors, and other targeted agents, the report provides valuable insights into the future directions of NSCLC treatment.
Key Questions Answered:
- How is AstraZeneca's Tagrisso currently used, and how might its use evolve with ongoing trials?
- What are the current and future uses of Genmab/Johnson & Johnson's Rybrevant?
- What impact will the subcutaneous formulation of Rybrevant have on its clinical use?
- What are the expectations for novel EGFR and HER tyrosine kinase inhibitors?
- How is Enhertu utilized in clinical practice for NSCLC?
- What are the views on recent approvals like Datroway, Emrelis, and Ensacove?
- How do experts use ALK inhibitors, and which are preferred?
- What is the potential of pipeline KRAS inhibitors in NSCLC treatment?
- How do specialists expect the MET, RET, ROS1, and BRAF inhibitors to change treatment algorithms?
- How is the targeted treatment landscape for NSCLC expected to evolve in the near-to-medium term?
Key Brands:
|
|
Partial List of Participating Experts:
- Assistant Professor of Medicine and Medical Oncologist, Duke University, US
- Jeffrey A. Brown and Barbara Horovitz Brown Associate, Professor of Translational Medicine, Director of Thoracic Oncology at the Lifespan Cancer Institute, in Providence, RI, US
- Director of the Thoracic Cancer Clinical Research Program and Associate Professor of Oncology at Johns Hopkins Medicine, MD, US
- Consultant Clinical Oncologist, Queen Elizabeth Hospital Birmingham, UK
- Professor and head of department, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France
- Head of the Thoracic Cancer Group in the Department of Medicine at Gustave Roussy, Villejuif, France
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
非小细胞肺癌(NSCLC)的全球市场，规模，占有率，趋势，产业分析报告:类别，不同治疗，各流通管道，各地区 - 市场预测，2025年～2034年
全球B型进行性纤维肉瘤转移性非小细胞肺癌市场（依国家及地区）分析与预测（2025-2035）
非小细胞肺癌治疗市场，按疗法、按配销通路、按癌症类型、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测
非小细胞肺癌治疗市场规模、份额、趋势分析报告：按类型、治疗方法、分销管道、地区和细分市场预测，2025 年至 2030 年
非小细胞肺癌市场 - 全球产业规模、份额、趋势、机会和预测，按类型、按治疗、按药物类别、按最终用户、按地区和竞争进行细分，2020-2030 年预测
非小细胞肺癌市场按类型、治疗、最终用户和地区划分
非小细胞肺癌市场规模、份额、成长分析、按类型、按治疗方法、按最终用途行业、按地区 - 行业预测，2025-2032 年
非小细胞肺癌市场：KOL 洞察
非小细胞肺癌治疗市场：按癌症类型、药物类别、分销管道划分 - 2025-2030 年全球预测
全球非小细胞肺癌市场：按类型、治疗类型、药物类别、通路和地区划分的评估、机会和预测（2016-2030）